- Home
- TMQ vs IMAB Comparison
TMQ vs IMAB Comparison
Compare TMQ & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- IMAB
- Stock Information
- Founded
- TMQ 2004
- IMAB 2014
- Country
- TMQ Canada
- IMAB United States
- Employees
- TMQ N/A
- IMAB N/A
- Industry
- TMQ Precious Metals
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TMQ Basic Materials
- IMAB Health Care
- Exchange
- TMQ Nasdaq
- IMAB Nasdaq
- Market Cap
- TMQ 249.6M
- IMAB 200.9M
- IPO Year
- TMQ N/A
- IMAB 2020
- Fundamental
- Price
- TMQ $1.55
- IMAB $5.15
- Analyst Decision
- TMQ
- IMAB Strong Buy
- Analyst Count
- TMQ 0
- IMAB 3
- Target Price
- TMQ N/A
- IMAB $6.33
- AVG Volume (30 Days)
- TMQ 398.2K
- IMAB 3.9M
- Earning Date
- TMQ 10-07-2025
- IMAB 05-15-2025
- Dividend Yield
- TMQ N/A
- IMAB N/A
- EPS Growth
- TMQ N/A
- IMAB N/A
- EPS
- TMQ N/A
- IMAB N/A
- Revenue
- TMQ N/A
- IMAB N/A
- Revenue This Year
- TMQ N/A
- IMAB N/A
- Revenue Next Year
- TMQ N/A
- IMAB N/A
- P/E Ratio
- TMQ N/A
- IMAB N/A
- Revenue Growth
- TMQ N/A
- IMAB N/A
- 52 Week Low
- TMQ $0.47
- IMAB $0.60
- 52 Week High
- TMQ $2.09
- IMAB $5.35
- Technical
- Relative Strength Index (RSI)
- TMQ 43.16
- IMAB 79.14
- Support Level
- TMQ $1.43
- IMAB $3.30
- Resistance Level
- TMQ $1.64
- IMAB $3.94
- Average True Range (ATR)
- TMQ 0.10
- IMAB 0.48
- MACD
- TMQ -0.03
- IMAB 0.20
- Stochastic Oscillator
- TMQ 22.55
- IMAB 97.12
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).